Seaport Therapeutics, Inc. SPTX
21.31 USD -0.66 (-3.00%)
At closeNov 11, 2026, 4:00 PM EST
21.31 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
20.26 Day range 21.83
14.85 52-week range 28.38
- YTD
- +7.41%
- 1 year
- +7.41%
News
benzinga.com JP Morgan Maintains Overweight on Seaport Therapeutics, Raises Price Target to $41 JP Morgan analyst Tessa Romero maintains Seaport Therapeutics (NASDAQ:SPTX) with a Overweight and raises the price target from $40 to $41.
zacks.com How Much Upside is Left in Seaport Therapeutics, Inc (SPTX)? Wall Street Analysts Think 77.91% The mean of analysts' price targets for Seaport Therapeutics, Inc (SPTX) points to a 77.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong…
benzinga.com Seaport Therapeutics Q3 EPS $(0.49) Beats $(0.58) Estimate Seaport Therapeutics (NASDAQ:SPTX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.58) by 15.52 percent. This is a 94.8 percent increase over losses of…
businesswire.com Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress.
seekingalpha.com Seaport Therapeutics: Borrowed Efficacy, Engineered Safety, And A Post-IPO Discount Seaport Therapeutics leverages proprietary Glyph technology to enhance bioavailability and safety for CNS drugs, targeting MDD and GAD markets. SPTX maintains a cash runway into 2029, with $427.3…
benzinga.com This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Analysts initiated coverage on VYLR, IMTX, ENTG, SLGL and SPTX, assigning Neutral, Buy or Overweight ratings and price targets.
benzinga.com Canaccord Genuity Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $28 Canaccord Genuity analyst Sumant Kulkarni initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $28.
gurufocus.com PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress [url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tran
businesswire.com PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Data from Phase 1 Trial of GlyphAgo at European College of Neuropsychopharmacology Congress.
gurufocus.com Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress [url="]Seaport Therapeutics, Inc.[/url] (Nasdaq: SPTX) (âSeaportâ or the âCompanyâ), a clinical-stage therapeutics company developing novel neuropsychia
benzinga.com Seaport Therapeutics To Present Phase 1 Clinical Data For GlyphAgo At The European College Of Neuropsychopharmacology Congress, October 10-13 Congress is taking place October 10-13, 2026, in Munich, Germany. The poster represents the first scientific presentation of data from the GlyphAgo Phase 1 program and provides detailed…
businesswire.com Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company developing novel neuropsychiatric medicines, today announced the…
benzinga.com HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
businesswire.com PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance.
businesswire.com Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance BOSTON--(BUSINESS WIRE)--Seaport Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo in Patients with Generalized Anxiety Disorder & Sleep Disturbance.
defenseworld.net Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Up – Should You Buy? Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report) gapped up before the market opened on Thursday. The stock had previously closed at $18.69, but opened at $20.12. Seaport Therapeutics…
defenseworld.net Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Down – What’s Next? Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report) shares gapped down before the market opened on Wednesday. The stock had previously closed at $19.64, but opened at $18.85. Seaport…
defenseworld.net Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Has Consensus Target Price of $38.57 Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve brokerages that are presently covering the firm, MarketBeat.com…
benzinga.com This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiated bullish coverage on TSEM, PGEN, SPTX, PDFS and CF, setting targets of $300, $12, $46, $60 and $162.- benzinga.com Raymond James Initiates Coverage On Seaport Therapeutics with Strong Buy Rating, Announces Price Target of $46 Raymond James analyst Tiago Fauth initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Strong Buy rating and announces Price Target of $46.
businesswire.com Seaport Therapeutics to Participate in September Investor Conferences BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric…- benzinga.com HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
seekingalpha.com Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
gurufocus.com PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers [url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tran
businesswire.com PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers.- benzinga.com Seaport Therapeutics Reports Phase 1 Results; GlyphAllo At 375 mg Meets Primary Endpoint With No Driving Impairment; 250 mg Dose Also Achieves Key Secondary Endpoint Trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosingKey…
businesswire.com Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers BOSTON--(BUSINESS WIRE)--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers.- benzinga.com Jones Trading Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $32 Jones Trading analyst Justin Walsh initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $32.
247wallst.com Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same…- benzinga.com HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
defenseworld.net Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week High – Here’s What Happened Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday. The company traded as high as $25.07 and last traded at $24.40, with a…
seekingalpha.com Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation Seaport Therapeutics leverages its Glyph platform to transform clinically validated molecules with poor delivery into proprietary, patent-protected prodrugs, reducing biological risk. GlyphAllo's…
benzinga.com HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.- benzinga.com Seaport Therapeutics Q2 EPS $(1.78) Misses $(0.65) Estimate Seaport Therapeutics (NASDAQ:SPTX) reported quarterly losses of $(1.78) per share which missed the analyst consensus estimate of $(0.65) by 173.85 percent. This is a 72.19 percent increase over…
- benzinga.com HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50 HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $50.
benzinga.com Seaport Therapeutics Q1 EPS $(10.34) Misses $(9.48) Estimate Seaport Therapeutics (NASDAQ:SPTX) reported quarterly losses of $(10.34) per share which missed the analyst consensus estimate of $(9.48) by 9.07 percent.- benzinga.com Citigroup Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $35 Citigroup analyst Yigal Nochomovitz initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $35.
- benzinga.com Leerink Partners Initiates Coverage On Seaport Therapeutics with Outperform Rating, Announces Price Target of $35 Leerink Partners analyst Marc Goodman initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Outperform rating and announces Price Target of $35.
- benzinga.com JP Morgan Initiates Coverage On Seaport Therapeutics with Overweight Rating, Announces Price Target of $42 JP Morgan analyst Tessa Romero initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Overweight rating and announces Price Target of $42.
benzinga.com Stifel Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $30 Stifel analyst Paul Matteis initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $30.